News | July 06, 2024
Nephro Care India lists at 90% premium
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
States urged to maintain a state of constant vigil through screening of pregnant women for Zika virus infection and monitoring the growth of foetus of expecting mothers who tested positive for Zika
Mahatma Gandhi Cancer Hospital & Research Institute has emerged as the leading provider of comprehensive cancer care in Viza
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Subscribe To Our Newsletter & Stay Updated
